RNXT

RenovoRx, Inc. [RNXT] Stock Forecast

Buy or Sell ? Support and Resistance
What is MACD and how to read it?
How RSI can help?
RSI : 000

RNXT Stock Summary

Top 10 Correlated ETFs

RNXT

Top 10 Correlated Stocks

RNXT

In the News

RNXT Financial details

Company Rating
-
Market Cap
20.58M
Income
-10.23M
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
8
Optionable
No
Shortable
Yes
Earnings
13 May 2024
P/E
-1.62
Forward P/E
-
PEG
0.47
P/S
-
P/B
2459.41
P/C
-
P/FCF
-1.49
Quick Ratio
2.01
Current Ratio
2.19
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-0.71
EPS next Y
-
EPS next Q
-
EPS this Y
-8.33%
EPS next Y
-
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-
-
-
-
-
SMA20
-23.94%
SMA50
-17.56%
SMA100
3.85%
Inst Own
-
Inst Trans
-
ROA
-258%
ROE
-342%
ROC
-6.16%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
-
Shs Float
-
-
-
-
-
Target Price
-
52W Range
0.531-3.29
52W High
-
52W Low
-
RSI
35.29
Rel Volume
1.88
Avg Volume
51.02K
Volume
96K
Perf Week
-10.43%
Perf Month
-24.82%
Perf Quarter
3%
Perf Half Y
-2.83%
-
-
-
-
Beta
1.041
-
-
Volatility
0.05%, 0.15%
Prev Close
0%
Price
1.03
Change
-7.21%

Something similar

Top by Market Cap
1YD.DE
VFINX
NVDA
TL0.DE
AMZN
Top Correlated ETFs
EPI
SMIN
PSCT
MDCP
FXP
Top Correlated Stocks
GHM
AYTU
SMTC
RICOY
ULTA
Similar Market Cap
VPC
CYXT
MLFMV.LS
BTC
GVFF

Company Profile

Healthcare Biotechnology
  • Volume Average 51.02K
  • Market Capitalization 20.58M
  • Employee 8
  • CEO Mr. Shaun R. Bagai
  • Headquarters Los Altos,CA,US
  • IPO Date 2021-08-26
  • Website https://renovorx.com

RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.